Business Context and Reporting Period
This Form 8-K Current Report was filed by Apimeds Pharmaceuticals US, Inc. (APUS) on September 10, 2026. The filing discloses the entry into a material definitive agreement and the appointment of a new director. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and legal settlements rather than financial performance.
Material Changes
- Amendment to Settlement Agreement: On September 10, 2026, the Company entered into the First Amendment to a Confidential Settlement and Mutual Release Agreement dated April 24, 2026. This amendment involves the Company, MindWave Innovations Inc., Lokahi Therapeutics, Inc., Erik Emerson, and the "Inscobee Parties" (FreeT Inc. and Apimeds Inc.).
- Board Restructuring: The Amendment restructures the Board of Directors. During the interim period until Preferred Stock Conversion, the Board consists of Elona Kogan, Carol O'Donnell, Dr. Bennett Weintraub, and Sungjoon Chae. Removal of these members requires written consent from Dr. Vin Menon and the Inscobee Parties.
- Future Board Composition: Post-interim, the Board will expand to seven members: four independent directors nominated by MindWave, two directors nominated by Dr. Vin Menon (including himself), and Sungjoon Chae.
- Director Appointment: Sungjoon Chae was appointed to the Board effective September 10, 2026, pursuant to a nomination by the Inscobee Parties.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. It notes that the material terms of Sungjoon Chae's compensation as a director have not yet been determined and will be disclosed once finalized. Mr. Chae has served as Co-Chief Executive Officer since May 4, 2026, and brings experience in real estate development and urban regeneration.
Investor Verification Checklist
- Review the full text of the First Amendment to the Confidential Settlement and Mutual Release Agreement (Exhibit 10.1) to understand the specific legal obligations and release terms.
- Verify the timeline and conditions for the "Preferred Stock Conversion" which triggers the transition to the seven-member Board structure.
- Monitor future filings for the finalized compensation arrangements for Director Sungjoon Chae.
- Confirm the current status of the Company's Preferred Stock and the identity of the holders involved in the settlement.